ATE553113T1 - Verwendung von lektinen zur förderung der oligomerisierung von glycoproteinen und antigenen molekülen - Google Patents

Verwendung von lektinen zur förderung der oligomerisierung von glycoproteinen und antigenen molekülen

Info

Publication number
ATE553113T1
ATE553113T1 AT04775814T AT04775814T ATE553113T1 AT E553113 T1 ATE553113 T1 AT E553113T1 AT 04775814 T AT04775814 T AT 04775814T AT 04775814 T AT04775814 T AT 04775814T AT E553113 T1 ATE553113 T1 AT E553113T1
Authority
AT
Austria
Prior art keywords
glycoproteins
molecules
lectins
lectin
promote oligomerization
Prior art date
Application number
AT04775814T
Other languages
English (en)
Inventor
James Zabrecky
Stephen Monks
Original Assignee
Agenus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Agenus Inc filed Critical Agenus Inc
Application granted granted Critical
Publication of ATE553113T1 publication Critical patent/ATE553113T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/17—Monocytes; Macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT04775814T 2003-02-28 2004-02-27 Verwendung von lektinen zur förderung der oligomerisierung von glycoproteinen und antigenen molekülen ATE553113T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45072103P 2003-02-28 2003-02-28
PCT/US2004/006047 WO2005020936A2 (en) 2003-02-28 2004-02-27 Use of lectins to promote oligomerization of glycoproteins and antigenic molecules

Publications (1)

Publication Number Publication Date
ATE553113T1 true ATE553113T1 (de) 2012-04-15

Family

ID=34272389

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04775814T ATE553113T1 (de) 2003-02-28 2004-02-27 Verwendung von lektinen zur förderung der oligomerisierung von glycoproteinen und antigenen molekülen

Country Status (10)

Country Link
US (1) US20040258705A1 (de)
EP (1) EP1603936B1 (de)
KR (1) KR20060026004A (de)
CN (1) CN1780850A (de)
AT (1) ATE553113T1 (de)
AU (1) AU2004268497A1 (de)
CA (1) CA2517396A1 (de)
ES (1) ES2395126T3 (de)
RU (1) RU2399381C2 (de)
WO (1) WO2005020936A2 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003072595A2 (en) * 2002-02-28 2003-09-04 Antigenics Inc. Methods and products based on oligomerization of stress proteins
US20050026866A1 (en) * 2002-08-02 2005-02-03 Pawelek John M. Agents and methods for treatment of disease by oligosaccharide targeting agents
KR100755931B1 (ko) * 2003-06-11 2007-09-06 (주)두비엘 고분자형 만노스 결합형 렉틴의 대량 생산방법 및 상기방법으로 제조된 만노스 결합형 렉틴 재조합 단백질의제제화
US7816149B2 (en) * 2004-03-29 2010-10-19 Applied Photonics Worldwide, Inc. Nanobioprocessor for protein and cell therapy
CN101094651B (zh) * 2004-12-30 2011-03-09 多贝尔有限公司 含有胶原凝集素家族蛋白质或者其变体的喷雾干燥的组合物和其制备方法
CN104761637B (zh) 2006-03-31 2021-10-15 中外制药株式会社 调控抗体血液动力学的方法
AU2007305166A1 (en) * 2006-10-03 2008-04-10 University Of Southern California GRP78 as a predictor of responsiveness to therapeutic agents
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
EP2257301B1 (de) 2008-03-03 2014-01-22 The University of Miami Auf allogenen krebszellen basierende immuntherapie
EP2275443B1 (de) 2008-04-11 2015-12-02 Chugai Seiyaku Kabushiki Kaisha Antigen bindendes molekül, das dazu in der lage ist, wiederholt zwei oder mehr antigenmoleküle zu binden
CN107970451A (zh) * 2010-10-01 2018-05-01 帆德制药股份有限公司 Tlr激动剂和联合治疗的治疗应用
TWI654204B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
US10357538B2 (en) 2012-12-24 2019-07-23 Northern Sydney Local Health District Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy
RU2511545C1 (ru) * 2013-02-07 2014-04-10 Федеральное государственное унитарное предприятие "Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") Способ антимикробной фотодинамической терапии острых воспалительных заболеваний гортаноглотки или их гнойных осложнений
NZ730607A (en) 2014-12-19 2022-07-01 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
SG10201710322VA (en) 2014-12-19 2018-02-27 Chugai Pharmaceutical Co Ltd Anti-c5 antibodies and methods of use
WO2016125495A1 (en) 2015-02-05 2016-08-11 Chugai Seiyaku Kabushiki Kaisha Antibodies comprising an ion concentration dependent antigen-binding domain, fc region variants, il-8-binding antibodies, and uses therof
KR102883915B1 (ko) 2015-12-16 2025-11-18 시애틀 프로젝트 코포레이션 신생항원 동정, 제조, 및 용도
PL3390442T3 (pl) * 2015-12-18 2024-03-18 Chugai Seiyaku Kabushiki Kaisha Przeciwciała anty-c5 i sposoby ich stosowania
BR112019001902A2 (pt) 2016-08-05 2019-07-09 Chugai Seiyaku Kabushiki Kaisha composição para profilaxia ou tratamento de doenças relacionadas à il-8
WO2018051085A1 (en) * 2016-09-13 2018-03-22 Centauri Therapeutics Limited Novel compounds and therapeutic uses thereof
US10707531B1 (en) 2016-09-27 2020-07-07 New Dominion Enterprises Inc. All-inorganic solvents for electrolytes
WO2019075112A1 (en) 2017-10-10 2019-04-18 Gritstone Oncology, Inc. IDENTIFICATION OF NEO-ANTIGENS USING HOT POINTS
KR20260008173A (ko) 2017-11-22 2026-01-15 시애틀 프로젝트 코포레이션 신생항원에 대한 접합 에피토프 제시 감소
KR20210005646A (ko) * 2018-04-26 2021-01-14 아게누스 인코포레이티드 열쇼크 단백질-결합 펩티드 조성물 및 그의 이용 방법
CN108587918A (zh) * 2018-05-30 2018-09-28 昆明理工大学 一种基于兼养微藻油脂积累的方法
CN112710843B (zh) * 2020-12-16 2022-11-04 江苏伟禾生物科技有限公司 一种测定群体反应性抗体检测的板式免疫荧光试剂盒及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0041426B1 (de) * 1980-05-22 1985-11-13 Institut Pasteur Kupplungsprodukt zwischen einem Lectin und einem spezifischen Liganden, Herstellung und Anwendung auf biologischem Gebiet
US5750119A (en) * 1994-01-13 1998-05-12 Mount Sinai School Of Medicine Of The City University Of New York Immunotherapeutic stress protein-peptide complexes against cancer
US5961979A (en) 1994-03-16 1999-10-05 Mount Sinai School Of Medicine Of The City University Of New York Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
US5985270A (en) 1995-09-13 1999-11-16 Fordham University Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
EP0851765A4 (de) 1995-09-13 2000-01-19 Univ Fordham Therapeutische und prophylaktische verfahren, welche hitzeschock-proteine einsetzen
US5837251A (en) 1995-09-13 1998-11-17 Fordham University Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
US5935576A (en) * 1995-09-13 1999-08-10 Fordham University Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
CA2389080C (en) * 1999-10-26 2012-02-21 Chiron Corporation Mistletoe lectins as mucosal adjuvants

Also Published As

Publication number Publication date
EP1603936A2 (de) 2005-12-14
WO2005020936A2 (en) 2005-03-10
WO2005020936A3 (en) 2005-06-23
KR20060026004A (ko) 2006-03-22
EP1603936A4 (de) 2007-07-25
RU2399381C2 (ru) 2010-09-20
CA2517396A1 (en) 2005-03-10
AU2004268497A1 (en) 2005-03-10
RU2005130173A (ru) 2006-03-10
US20040258705A1 (en) 2004-12-23
ES2395126T3 (es) 2013-02-08
EP1603936B1 (de) 2012-04-11
CN1780850A (zh) 2006-05-31

Similar Documents

Publication Publication Date Title
WO2005020936A3 (en) Use of lectins to promote oligomerization of glycoproteins and antigenic molecules
CY1112055T1 (el) Συνθεσεις και μεθοδοι για την διαγνωση και θεραπευτικη αγωγη ογκου πνευμονα
TR200301846T2 (tr) Cripto bloke edici Antikorlar ve bu antikorların kullanımları.
MX2021008800A (es) Barrera hematoencefalica humana in vitro.
YU37304A (sh) Specifični agensi koji vezuju humani angiopoetin-2
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
BRPI0507680A (pt) partìculas de fosfato de cálcio terapêuticas e métodos de fabricação e uso das mesmas
TNSN07150A1 (en) Semi-soft c-class immunostimulatory oligonucleotides
WO2001052791A3 (en) Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
DE60335383D1 (de) Antikörper mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen
CY1109741T1 (el) Sns-595 και μεθοδοι χρησης αυτου
DE50306232D1 (de) Ampholytisches copolymer und dessen verwendung
FI20011671A7 (fi) Tuumorispesifiset oligosakkaridisekvenssit ja niiden käyttö
TW200607863A (en) Immune modulating compounds from fungi
DE602004017326D1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung
ATE489103T1 (de) Gezielte thrombose durch gewebefaktor polypeptiden
DE60215627D1 (de) Impfstoff zur modulation zwischen t1 und t2 immunantworten
DE60219940D1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
ATE476987T1 (de) Zusammensetzungen und methoden zur behandlung von candidosen
ATE293991T1 (de) VERWENDUNG EINES MIT DEM PEPTID ßELAGIGILTVß ASSOZIIERTEN ENTEROBAKTERIEN-PROTEINS OMPA ZUR BEHANDLUNG VON MELANOMEN
DE60231971D1 (de) Ndet, und seine verwendung zur behandlung von krebs
ATE536887T1 (de) Kovalente konjugate zwischen mit artemisinin verwandten endoperoxiden und eisentragenden proteinen und anwendungsverfahren
ATE460168T1 (de) Nicht-radioaktives strontiummittel zur behandlung von krebs
DE60327925D1 (de) Verwendung von löslichem fgl2 als immunosuppressivum
ATE414776T1 (de) Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten